Thank you for supporting SEI Healthcare. We invite you to embrace Skymedcare. For any questions, please kindly contact us.

Short Bowel Syndrome: A journey through the age spectrum using evidence-based practice – Intermediate Level

Introduction

Short bowel syndrome (SBS) is a rare, complex and sometimes debilitating chronic condition associated with significant morbidity and mortality, impaired quality of life (QoL) and substantial economic burden.1,2

SBS is most commonly acquired, although newborns may present with congenital short bowel.3 Acquired SBS is frequently associated with extensive and/or multiple surgical resections to treat intestinal diseases such as inflammatory bowel disease (IBD), injury/trauma, or birth defects.3,4 In the US, fewer than 50,000 people have SBS.5

Despite improvements in awareness and management of SBS, there remain several unmet needs.2 Comprehensive management requires an understanding of gastrointestinal (GI) anatomy and physiology, a dedicated multidisciplinary team, and management of nutrition/fluids, medications, and comorbidities.1 Patients often struggle to maintain nutrition and hydration status. Using a combination of diet and pharmacotherapies, partial or full enteral autonomy may be achievable over time through intestinal adaptation.6 In selected patients, augmentation of the absorptive capacity of the existing small bowel may be achieved with glucagon-like peptide 2 (GLP-2) analog therapy, leading to significantly improved QoL.6

Faculty

John K. DiBaise, MD:
Professor of Medicine and Consultant, Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ.

Stephanie Oliveira, MD, CNSC:
Associate Medical Director, Intestinal Rehabilitation Program, and Assistant Professor at UC Department of Pediatrics, Cincinnati Children’s, Cincinnati, OH.

Carol Rees Parrish, MS, RDN (Moderator):
GI Nutrition Support Specialist,UVA Health (retired), Charlottesville, VA.

Educational needs and learning objectives

The goals of this project are to provide education for HCPs working in Gastroenterology, Pediatrics, Internal Medicine, Surgery, and Primary Care, who are involved in the care of adult and pediatric patients with SBS. The primary objectives of this educational activity are to:

  • Improve HCP awareness of SBS and overall care of patients with SBS across different settings and age groups.
  • Improve HCP knowledge of current diagnosis and treatment guidelines and recommendations regarding the management of SBS in adult and pediatric patients.
  • Improve HCP knowledge of the efficacy and safety data of symptomatic and disease-specific pharmacotherapies, particularly glucagon-like peptide-2 (GLP-2) analogues.
  • Facilitate HCP access to relevant, culturally sensitive educational materials that are appropriate for a patient and/or caregiverʼs needs.

Learning objectives

After completing this educational activity, learners should be able to:

  • Review current definitions of SBS and IF, and list key physiological changes/needs during different phases of intestinal adaptation to identify the patient’s age-appropriate treatment goals (e.g., growth, reduce PN volume, time off/eliminate need for PN).
  • List common pitfalls in the management of chronic SBS-IF, including identifying the SBS-IF patient, challenges in hydration, monitoring for micronutrient deficiencies, and identifying patients on chronic PN for whom it may be possible to reduce or eliminate PN needs.
  • Using current guidelines and recommendations, provide an overview of SBS management across the age span from infancy to adulthood, inclusive of different nutritional/hydration, pharmacological, and surgical therapies, integrating management strategies that promote intestinal absorption (e.g., teduglutide).
  • Summarize key efficacy and safety data pertaining to drugs specifically approved for use in SBS and apply this information to treatment decision-making, aiming to maximize quality of life and achieve enteral autonomy where possible.

Target Audience

This activity is intended for HCPs  involved in the care of people with SBS practicing in the United States: Gastroenterologists, Pediatricians, Pediatric Gastroenterologists, Internal Medicine Specialists, Surgeons (including Colorectal Surgeons), Primary Care Physicians,  Dietitians, Advanced Practice Providers (Nurse Practitioners and Physician Assistants),  Nurses, Pharmacists, Psychologists and Social Workers.

Enduring Materials CE Activity

Release Date: August 26, 2024

Expiration Date: November 26, 2025

Continuing Education Information

This continuing education activity is provided by AffinityCE and  Skymedcare LLC. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, nurses, and pharmacists. A statement of participation is available for other attendees.

Disclosures

Faculty disclosures

Dr. Stephanie Oliveira  has disclosed the following financial relationships:

  • Consultant: Takeda

Dr. John DiBaise has disclosed the following financial relationships:

  • Consultant and Advisory Board: Takeda
  • Principal investigator (Clinical Trial): Zealand Pharmaceuticals
  • Clinical Trial: North Sea Therapeutics

Carol Parrish, MS, RDN has disclosed the following financial relationships:

  • Consultant: Takeda

AffinityCE staff, Skymedcare staff, planners, and reviewers have no relevant financial relationships to disclose. All faculty disclosures are listed below, available on the program website, and will be stated prior to the start of each presentation.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships reported have been mitigated prior to the commencement of the activity through peer review of content by non-conflicted reviewers.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Skymedcare. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring materials activity for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and SEI-Healthcare. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring materials activity for a maximum of 2 AMA PRA Category 1 Credit™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Skymedcare. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring materials activity for a maximum of 2 AMA PRA Category 1 Credit™. Nurse Practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education is provided for this activity through the joint providership of AffinityCE and Skymedcare. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides 1.0 contact hour of continuing nursing education credit.

Pharmacists

AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This knowledge-based CPE activity will provide 1.0 contact hour for participants. There is no cost to participate. Participant CE records will be electronically communicated to CPE Monitor. UAN: 0829-9999-24-161-H01-P

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Commercial Support

Educational Support for this activity was provided by an independent medical educational grant from Takeda.

Participation Costs

There is no cost to participate in this CE activity.

CME Inquiries

For all CME policy-related inquiries, please contact us at [email protected]

How to Earn CE Credit

Physicians, Physician Assistants, Nurse Practitioners, Nurses and other health professionals

1.Go to the following web site:https://my-ime.com/

2.Register or enter your profile ID.

3.Complete the activity. Your CE records will be electronically sent  to and maintained on your Learner dashboard.

Pharmacists

1. Go to the following website (click here)

2. Login and enter your eProfile ID.

3. Your Pharmacy CE records will be electronically communicated to CPE Monitor.

References:

1) Parrish CR, et al. Gastroenterol Hepatol (N Y). 2017;13(10):600–608.
2) DiBaise JK. Nutr Clin Pract. 2023;38(Suppl 1):S4–S8.
3) National Organization for Rare Diseases –  Short bowel syndrome. www.rarediseases.org/rare-diseases/short-bowel-syndrome. Accessed April 6, 2022.
4) Short bowel syndrome. Treasure Island (FL):  StatPearls  Publishing. www.ncbi.nlm.nih.gov/books/NBK536935. Updated July 26, 2022. Accessed April 6, 2023.
5) Genetic and Rare Diseases Information Center – Short bowel syndrome. www.rarediseases.info.nih.gov/diseases/1502/short-bowel-syndrome. Accessed April 6, 2023.
6) Copland A, et al. Pract Gastroenterol. 2017;September 2017:41–52.

Free

FREE

Disclaimer

This independent medical education program has been supported by an educational grant from Takeda. The educational program has been developed by SkymedCare in cooperation with AffinityCE, and it is intended for healthcare professionals practicing in the United States. 

The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient. For full prescribing information for all products, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Please note that products may have different product labeling according to geographical location; within the United States, full prescribing information is available from the US Food and Drug Administration (fda.gov). 

All characters and events depicted in this activity are entirely fictitious. Any similarity to actual events or persons, living or dead, is purely coincidental.

The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient.